Bringing HLA-A*02-directed CAR T to Solid Tumor Care With the EVEREST-1 Trial
May 22nd 2023Diane M. Simeone, MD, discussed the phase 1/2 EVEREST-1 trial, which seeks to assess the novel CAR T-cell therapy A2B530 in patients with solid tumors—hopefully progressing one-and-done engineered therapies in this population.
BASECAMP-1: Trial of Novel CAR T-Cell Agent Seeks Patients Eligible for Treatment
April 20th 2023Investigators have initiated the BASECAMP-1 trial of investigational agent A2B530 with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial.